According to our results, PAC1 receptor agonists, particularly if biased towards anti‐fibrotic signaling, could hold therapeutic potential to attenuate metabolically triggered cardiac fibrosis and would represent a much‐needed therapeutic option for the treatment of this adverse tissue remodeling, occurring frequently in cardiac disease. Here, ADCYAP1R1 is linked to heart disorder.